Quantcast

Latest Hepatitis C and HIV co-infection Stories

2014-07-25 09:45:29

University of Cincinnati Academic Health Center Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published Wednesday, July 23, 2014, in Science Translational Medicine. Previously, physicians treating co-infected patients worried that HIV antiretroviral therapy might injure the liver...

2014-07-21 11:07:15

The JAMA Network Journals HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference. Up to 7 million persons worldwide are infected with both human...

2014-07-15 12:28:37

Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the hepatitis C virus (HCV) population is large with more than 2 million diagnosed, chronically infected cases throughout the G7 markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Many of these patients, including more than 270,000 with...

2014-07-01 12:27:54

- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/ -- Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM)...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-05-22 08:29:21

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL, May 22, 2014 /CNW/ - AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including...

2014-05-19 10:12:50

University at Buffalo More effective, new medications for HCV infection with fewer side effects also are causing a shift in patients’ attitudes People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus, according to a study by researchers at several institutions, including the University at Buffalo. That finding, published online this week in the Journal of Addiction Medicine will be welcome news to...

2014-05-02 12:26:36

New research finds Vietnam vets with hepatitis C do not have higher rates of the disease DANVILLE, Pa., May 2, 2014 /PRNewswire-USNewswire/ -- A team of researchers from four health systems across the United States has published a study revealing that Vietnam era vets with hepatitis C virus (HCV) do not have higher rates of this disease due to injection drug abuse compared to nonveterans. The study was published electronically in the Journal of Community Health in April. It is...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related